Renal Cell Neoplasia Tables: Recurrent Cytogenomic Alterations: Difference between revisions
| [unchecked revision] | [unchecked revision] |
m updated citation |
m added footer |
||
| Line 336: | Line 336: | ||
|[12, 76, 102, 103, 105, 129, 132, 135-137, 140, 178-180] | |[12, 76, 102, 103, 105, 129, 132, 135-137, 140, 178-180] | ||
|} | |} | ||
Note: <sup>a</sup> level of evidence (ranges from level 1 to 3 as specified in the methods). Level 1, established clinical significance and present in current WHO classification and/or professional practice guidelines such as NCCN, ASCO, CAP guidelines or FDA approval; Level 2, recurrent clinical significance based on large studies with outcomes; and Level 3, recurrent but uncertain clinical significance based on smaller studies and multiple case reports. | |||
<sup>b</sup> clinical significance, D-diagnosis, P-prognosis, R-recurrence | |||
<sup>c</sup> alterations in combination | |||